uniQure N.V. - Ordinary Shares - Bilanço (NASDAQ:QURE)

Financials

Toplam varlıklar 340.39 M809.18 M704.96 M831.69 M556.54 M824.91 M Toplam yükümlülükler 96.49 M213.4 M228.96 M624.02 M563.29 M626.01 M Toplam özsermaye 243.91 M595.78 M476.01 M207.67 M-6.75 M198.9 M Toplam yükümlülükler ve hissedarların özsermayesi 340.39 M809.18 M704.96 M831.69 M556.54 M824.91 M Toplam borç 35.62 M100.96 M102.79 M101.75 M51.32 M49.7 M Net borç 35.62 M100.96 M102.79 M101.75 M51.32 M-573.15 M

uniQure N.V. - Ordinary Shares

uniQure is a Dutch biopharmaceutical company which makes gene therapies. It has developed several adeno-associated virus gene therapies.

QURE

Financials

uniQure N.V. - Ordinary Shares

Haberler

Biotech Investors Are Tuning Out the MAHA Chaos

uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

uniQure, Huntington tedavisi için İngiltere’ye başvuracak

Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis

Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last?

uniQure Investors Sue Company Over Huntington’s Disease Drug Study Claims - TipRanks.com

Biotechs Breathe Easy As Vinay Prasad Plans His Exit. But Should They?

PGIM Jennison Health Sciences Fund Q4 2025 Key Contributors And Detractors

A Unique Situation For UniQure (QURE)

Mizuho, FDA liderlik değişikliği sonrası uniQure hissesini yükseltti

Mizuho upgrades uniQure stock rating on FDA leadership change

Avago, Lumentum among market cap stock movers on Monday